COMMUNIQUÉS West-GlobeNewswire

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
09/01/2025
PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
09/01/2025
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company [...]
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
09/01/2025
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for [...]
BioV Life Science and Regenerative Medicine International Summit Successfully Concludes, Leading the Future of Regenerative Medicine
09/01/2025
Los Angeles, CA, Jan. 09, 2025 (GLOBE NEWSWIRE) -- On December 22, 2024, the "BioV Life Science and Regenerative Medicine International Summit," a significant event in the life sciences field at the end of 2024, [...]
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
09/01/2025
Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase 3 HAELO study [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2025
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Partnering to Save Lives, NMDP and the American Football Coaches Association Promote Student Athlete Philanthropy
09/01/2025
AFCA’s Support of NMDP Get in the Game Invites College Coaches and Student Athletes to Help Give More Patients a Second Chance at Life Through Blood Stem Cell Donations MINNEAPOLIS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- [...]
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
09/01/2025
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – [...]
LifeLabs’ President and CEO, Charles Brown, named one of the “Top 50 Healthcare Technology CEOs of 2024”
09/01/2025
Toronto, Ontario, Jan. 09, 2025 (GLOBE NEWSWIRE) -- We are pleased to share that LifeLabs’ President and CEO, Charles Brown, has been named one of the “Top 50 Healthcare Technology CEOs of 2024” by The Healthcare [...]
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
09/01/2025
MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43 r d Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at [...]
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
09/01/2025
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing [...]
New Book "Prescribed Malnutrition: An Oncology Nutrition Narrative Review" Announces Critical Insights into Cancer Nutrition Misconceptions
09/01/2025
New book exposes cancer diet myths, debunks misconceptions about fasting, sugar, and dairy, and advocates evidence-based nutrition to support patients through oncology treatment Bucharest, Romania, Jan. 09, 2025 (GLOBE [...]
Cytosurge Announces Strategic Leadership Transition
09/01/2025
Simon Egli Appointed Chief Executive Officer as Co-Founder Pascal Behr Transitions to Board of Directors ZÜRICH, Switzerland, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, a leader in single-cell manipulation, a [...]
H.H.C. Group Successfully Completes URAC Monitoring Validation Review as Independent Review Organization
09/01/2025
ROCKVILLE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C), the leader in reducing healthcare costs by providing high-quality cost containment using claim negotiation, repricing and independent review [...]
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
09/01/2025
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class [...]
AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals
09/01/2025
BERWYN, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today launched its latest Specialty & Rare Pipeline [...]
Carestream’s Focus HD Detectors, DRX-Rise Mobile X-ray System Receive European Union CE Marking Approval
09/01/2025
ROCHESTER, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Carestream Health today announced today it received European Union CE Marking Approval for both its Focus HD Detectors and DRX-Rise Mobile X-ray System. “This is an [...]
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
09/01/2025
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the AMPA-associated protein, [...]
BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco
09/01/2025
Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech Showcase during JP [...]

Pages